Results show that lncRNA ANRIL plays a key role in non-small cell lung cancer (NSCLC) development by associating its expression with survival in patients with NSCLC through silencing of KLF2 and P21 transcription.

Our results suggested that lncRNA ANRIL was a potential biomarker for non-small cell lung cancer prognosis

ANRIL was identified as an oncogene involved in a number of tumors such as gastric cancer, lung cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma. Inhibition of ANRIL suppressed the cancer cell proliferation, migration and invasion. Review.

findings might improve lung adenocarcinoma (LAD) patients' paclitaxel treatment and made ANRIL to be a new target for paclitaxel-based chemotherapy in LAD

CDKN2B-AS1 rs2151280 T>C was associated with the risk of lung cancer.

Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR98 in lung cancer cells.